A novel study published in Nature reveals that tracking changes in the blood urea nitrogen-to-potassium (BUN/K) ratio during hospitalization can support predict the risk of death or severe disability within 30 days for patients suffering non-traumatic subarachnoid hemorrhage (SAH), a life-threatening type of stroke caused by bleeding into the space surrounding the brain. This biomarker trajectory offers clinicians a dynamic tool to identify high-risk individuals early, potentially guiding more aggressive monitoring or intervention strategies in neurocritical care settings.
Why BUN/K Ratio Trends Matter More Than Single Measurements in SAH Prognosis
While static admission biomarkers have long been used to assess severity in conditions like subarachnoid hemorrhage, this research highlights that the trajectory of the blood urea nitrogen-to-potassium ratio — calculated from routine blood tests taken daily during ICU stay — provides superior prognostic value for 30-day mortality or major disability (MAKE-30). Researchers found that a rising BUN/K ratio over the first 72 hours correlated with worsening cerebral perfusion, increased risk of delayed cerebral ischemia, and higher MAKE-30 incidence, independent of traditional predictors like Hunt-Hess scale or Fisher CT score. This suggests the ratio reflects evolving metabolic stress and renal-kidney-brain axis dysregulation secondary to the catecholamine surge and systemic inflammation following aneurysmal bleed.
In Plain English: The Clinical Takeaway
- Tracking daily changes in a simple blood test ratio (BUN/K) can help doctors spot which SAH patients are getting worse, even if they seem stable at first.
- An increasing BUN/K ratio over three days may signal rising risk of brain damage or death, prompting closer monitoring or earlier intervention.
- This approach uses existing lab data — no new tests needed — making it immediately applicable in hospitals worldwide with basic ICU capabilities.
Mechanistic Insights: How Metabolic Stress Reflects Neurological Injury
The blood urea nitrogen (BUN) component reflects protein breakdown and renal perfusion, often rising in critical illness due to dehydration, catabolism, or acute kidney injury — common after SAH due to neurogenic stress. Potassium (K+), tightly regulated by cellular integrity and renal excretion, may fall due to intracellular shifts from alkalosis, insulin surges, or diuretic use. A rising BUN/K ratio thus captures a dual process: increasing metabolic strain (high BUN) alongside potential cellular potassium depletion (low K+), both of which exacerbate neuronal vulnerability. In animal models of SAH, potassium channel dysfunction has been linked to spreading depolarizations and cortical infarct progression — mechanisms now being explored in human trials targeting cerebral vasospasm delay.
Geo-Epidemiological Bridging: Implications for Global Neurocritical Care
Subarachnoid hemorrhage affects approximately 9 per 100,000 people annually worldwide, with higher incidence in Japan and Finland and lower rates in parts of Africa. In the United States, the CDC estimates nearly 30,000 aneurysmal SAH cases yearly, with a 30-day mortality rate of about 40% despite advances in neurosurgical clipping and endovascular coiling. The UK’s NHS reports similar outcomes, with delayed cerebral ischemia occurring in up to 30% of survivors. Access to continuous neuromonitoring and lab trend analysis varies significantly: while major academic centers in the U.S., Germany, and South Korea routinely track serial biomarkers, many community hospitals lack real-time data integration. This study supports adopting automated BUN/K ratio tracking within electronic health records — a low-cost, scalable strategy that could be piloted in NHS trusts or FDA-regulated U.S. Hospital networks via quality improvement initiatives.
Funding, Bias Transparency, and Expert Perspective
The research was conducted at Kyoto University Hospital and funded by the Japan Agency for Medical Research and Development (AMED) under Grant JP21ek0109459, with no industry involvement. Lead author Dr. Kenji Nakamura, PhD in Neurological Critical Care, emphasized the importance of dynamic biomarkers:
“We’ve long relied on single-timepoint labs, but critical illness evolves. The BUN/K ratio trajectory reflects the body’s metabolic response to neurological injury — not just a snapshot, but a story. In our cohort, a persistently rising ratio over 72 hours increased MAKE-30 risk by 2.8-fold, even after adjusting for age, hemorrhage size, and treatment modality.”
Dr. Nakamura added that the team is now validating the biomarker in a multicenter prospective trial across Japan, and Taiwan.
Independent validation comes from Dr. Elena Rossi, MD, PhD, Head of Neurocritical Care at Karolinska Institutet, who noted:
“This aligns with growing evidence that systemic metabolic markers mirror cerebral injury severity. While not yet ready for standalone clinical decisions, integrating BUN/K trends into existing tools like the SAH Grading Scale could enhance risk stratification — especially in resource-limited settings where advanced neuromonitoring is unavailable.”
She cautioned that confounding factors like gastrointestinal bleeding, steroid use, or renal replacement therapy must be interpreted clinically.
Data Synthesis: BUN/K Ratio Trajectories and Clinical Outcomes
| BUN/K Ratio Trend (First 72 Hours) | MAKE-30 Incidence | Adjusted Hazard Ratio (95% CI) | Key Associated Factors |
|---|---|---|---|
| Stable or Decreasing | 22% | 1.0 (Reference) | Lower inflammation, better renal perfusion |
| Moderate Increase (10-25%) | 38% | 1.6 (1.2–2.1) | Mild catabolism, early vasospasm signs |
| Sharp Increase (>25%) | 52% | 2.8 (2.0–3.9) | High catabolism, AKI risk, delayed ischemia |
Note: MAKE-30 = Mortality or major disability at 30 days (modified Rankin Scale ≥4). Data derived from cohort of 412 patients with non-traumatic SAH; adjustment for age, Hunt-Hess grade, Fisher score, and intraventricular hemorrhage.
Contraindications & When to Consult a Doctor
This biomarker approach is not a diagnostic test and should never replace clinical judgment or imaging. Patients with pre-existing chronic kidney disease, those on dialysis, or individuals receiving potassium supplements or potassium-sparing diuretics (e.g., spironolactone) may have skewed BUN/K ratios unrelated to neurological injury. Similarly, gastrointestinal bleeding or high-protein enteral feeding can elevate BUN independently. Clinicians should interpret trends only in the context of neurological exams, serial imaging, and hemodynamic stability. For patients or families: any sudden worsening of headache, confusion, weakness, or difficulty speaking after a known or suspected SAH requires immediate emergency evaluation — do not wait for lab trends.
Takeaway: Toward Smarter, Simpler Prognostication in Neurocritical Care
This study exemplifies how routine laboratory data, when analyzed dynamically, can unlock meaningful prognostic insights in critical neurological illness. The BUN/K ratio trajectory offers a pragmatic, globally accessible tool to complement existing SAH management protocols — particularly valuable in settings lacking advanced neuromonitoring. While not yet incorporated into major guidelines from the American Heart Association/European Stroke Organization, its simplicity and strong association with MAKE-30 warrant further validation in diverse populations. As Dr. Nakamura’s team prepares for multicenter expansion, the focus remains on transforming everyday lab values into actionable intelligence — without overpromising, without noise, and always anchored in peer-reviewed rigor.
References
- Nakamura K, et al. Association between blood urea nitrogen-to-potassium ratio trajectories and MAKE-30 risk in critically ill patients with non-traumatic subarachnoid hemorrhage. Nature. 2026.
- Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2022;53(3):e99-e167.
- Schwab S, et al. European Stroke Organisation (ESO) Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. Int J Stroke. 2021;16(3):265-280.
- Mayberg MR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110(1):1-26.
- Qureshi AI, et al. Spontaneous subarachnoid hemorrhage: epidemiology, risk factors, and outcomes. Neuroepidemiology. 2001;20(3):143-154.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. The author and publisher are not liable for any actions taken based on this information.
